Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Garabedian joined Perceptive Advisors to develop their Venture Fund strategy and launched the Perceptive Xontogeny Venture Fund in 2018 to support early-stage companies seeded and incubated at Xontogeny and other ventures.
Garabedian has a broad base of experience and a track record of success over his decades-long experience in the biopharma industry. He served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial-stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Prior to Sarepta, Garabedian led Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, he served in a number of global commercial and corporate development leadership roles at Gilead from 1997 to 2005.
Garabedian serves on a number of Boards of life sciences companies and speaks at industry conferences on a wide range of important issues. He is also on the Board of Directors of MassBio and serves as a Senior Advisor for the Boston Consulting Group.
Garabedian received his BS in marketing from the University of Maryland.